Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	41340-25-4
Formula :	C₁₇H₂₁NO₃
M.W :	287.35
SMILES Code :	O=C(O)CC1(CC)OCCC2=C1NC3=C2C=CC=C3CC
Synonyms :	AY-24236; NIH 9918; NSC 282126
MDL No. :	MFCD00133313
InChI Key :	NNYBQONXHNTVIJ-UHFFFAOYSA-N
Pubchem ID :	3308

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H319-H350-H360
Precautionary Statements:	P264-P270-P280-P301+P310+P330-P305+P351+P338-P337+P313-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Rabbit articular chondrocytes	6.3 µM	10 min	Inhibited TNFα-induced ICl,vol activation, preventing apoptotic volume decrease (AVD) and elevation of caspase-3/7 activity	Int J Mol Sci. 2013 Sep 30;14(10):19705-15.
MRC-5	0.125 mM, 0.25 mM, 0.5 mM, 1 mM	72 hours	No growth inhibition was observed.	Cancer Sci. 2004 Aug;95(8):666-73.
PrEC normal prostatic epithelial cells	400 µM (ID50)	72 hours	Assess the effect of R-etodolac on normal epithelial cells, demonstrating weaker inhibition compared to cancer cells	Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30.
LNCaP prostate cancer cells	150 µM (ID50)	72 hours	Evaluate the inhibitory effect of R-etodolac on prostate cancer cell proliferation, showing significant inhibition of LNCaP cell growth	Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30.
PLC/PRF/5	0.125 mM, 0.25 mM, 0.5 mM, 1 mM	72 hours	Etodolac inhibited the growth of PLC/PRF/5 cells and induced cell cycle arrest.	Cancer Sci. 2004 Aug;95(8):666-73.
HepG2	0.125 mM, 0.25 mM, 0.5 mM, 1 mM	72 hours	Etodolac inhibited the growth of HepG2 cells and induced cell cycle arrest.	Cancer Sci. 2004 Aug;95(8):666-73.
Primary prostate cancer explants	≥500 µM		R-etodolac induced apoptosis in malignant cells while adjacent normal prostatic epithelium remained morphologically intact	Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30.

TRAMP transgenic mice	Prostate cancer model	Oral	1.25 mg/kg	Continuous for 2 weeks or from 9-12 weeks of age until 30 weeks	R-etodolac significantly inhibited tumor progression and metastasis, selectively inducing apoptosis in tumor cells, reducing tumor mass and metastasis frequency	Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2525-30.
Wistar rats	Collagen-induced arthritis (CIA) model	Oral gavage	5 mg/kg	Once daily for 7 months	Etodolac significantly alleviated synovial inflammation, fibrosis, and hyperplasia in CIA rats by downregulating proteins in the complement and coagulation cascades, and platelet degranulation cluster.	Mol Biomed. 2021 Oct 25;2(1):33

{[proInfo.proName]}

CAS No.: 41340-25-4

{[proInfo.proName]}

CAS No.: 41340-25-4

Alternative Products

Product Details of Etodolac

Safety of Etodolac

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01506154	Bursitis Tend... More >>onitis Shoulder Pain Less <<	Phase 3	Completed	-	-
NCT00527319	Cachexia	Phase 2	Completed	-	United States, Texas ... More >> First Dynamic Health Care Services, Inc. Waco, Texas, United States, 76708 India Rajalakshmi Nursing Home Bangalore, India Nizam Institute of Medical Sciences Hyderabaad, India Orchid Nursing Home Kolkata, India Shatabdi Super Specialty Hospital Nashik, India All India Institute of Medical Sciences New Delhi, India Indraprastha Apollo Hospital New Delhi, India Deenanath Mangeshkar Hospital Pune, India Less <<
NCT01638962	Osteoarthritis, Knee	Not Applicable	Completed	-	Denmark ... More >> University of Southern Denmark Odense, Region Syddanmark, Denmark, 5230 Less <<
NCT03763006	Dry Eye	Phase 1 Phase 2	Recruiting	February 2019	Singapore ... More >> Singapore Eye Research Institute Recruiting Singapore, Singapore, 169856 Contact: Cynthia Boo, BSc 65767200 cynthia.boo.s.k@seri.com.sg Less <<
NCT02180516	-		Completed	-	-
NCT00527319	-		Completed	-	-
NCT00888797	Colorectal Neoplasms	Phase 3	Unknown	January 2017	Israel ... More >> Rabin- Beilinson Medical Center Not yet recruiting Petah Tikva, Israel Contact: Nir Wasserberg, M.D. nirw@clalit.org.il Principal Investigator: Nir Wasserberg, M.D. Tel Aviv-Sourasky Medical Center Not yet recruiting Tal Aviv, Israel Contact: Hagit Tulchinsky, M.D. hagitt@tasmc.health.gov.il Principal Investigator: Hagit Tulchinsky, M.D. Sheba Medical Center Recruiting Tel Hashomer, Israel, 45858 Contact: Oded Zmora, M.D. 972-3-5302247 ozmora@post.tau.ac.il Principal Investigator: Oded Zmora, M.D. Sub-Investigator: Marat Khaikin, M.D. Less <<
NCT00502684	Primary Operable Breast Cancer	Not Applicable	Unknown	January 2016	Israel ... More >> Rabin Medical Center Recruiting Petah Tikva, Israel, 49100 Contact: Eran Sharon, MD +972-3-9376213 erans@clalit.org.il Contact: Irit Glik +972-3-9376717 IritGlik@clalit.org.il Principal Investigator: Eran Sharon, MD Sheba Medical Center Recruiting Ramat Gan, Israel, 52621 Contact: Moshe Shabtai, MD 972-3-5302247 Moshe.Shabtai@sheba.health.gov.il Contact: Maytal Shabat-Simon, PhD 972-50-2624233 maytal.shabat@gmail.com Principal Investigator: Moshe Shabtai, MD Kaplan Medical Center Recruiting Rehovot, Israel, 76100 Contact: Tanir M Allweis, MD +972-50-7874268 taniral@clalit.org.il Contact: Maytal Shabat-Simon, PhD 972-50-2624233 maytal.shabat@gmail.com Principal Investigator: Tanir M Allweis, MD Less <<
NCT00151736	Chronic Lymphocytic Leukemia	Phase 2	Terminated	-	France ... More >> Chef du Service d'Hematologie Clinique CHU Clemenceau Caen, France Service maladies du sang CHRU- rue Michel Polonovski Lille, France Germany Charité - Benjamin Franklin Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin Berlin, Germany Internistische Schwerpunktpraxis Erlangen, Germany Medizinische Poliklinik der Universität Hämatologie/Onkologie Würzburg, Germany Poland Samodzielny Publiczny Szpital Kliniczny AM Klinika Hematologii Bialystok, Poland Samodzielny Publiczny Szpital Kliniczny Nr 1 Akademickie Centrum Kliniczne Akdemii Medycznej w Gdansku Klinika Hematologii Gdansk, Poland Uniwersytet Jagiellonski Collegium Medicum Katedra i Klinika Hematologii Krakow, Poland Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Klinika Hematologii Instytutu Medycyny Wewnetrznej Uniwersytetu Medycznego w Lodzi Lodz, Poland Prywatna Praktyka Lekarska z Osrodkiem Badan Klinicznych Prof. L. Szczepanskiego Lublin, Poland Samodzielny Publiczny Centralny Szpital Kliniczny Katedra i Klinika Hematologii Onkologii i Chorob Wewnetrznych AM Warszawa, Poland Samodzielny Publiczny Szpital Kliniczny Nr 1 Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku Wroclaw, Poland Sweden Centrum för Hematologi Karolinska Universitetssjukhuset, Solna Stockholm, Sweden Hematologkliniken Karolinska Universitetssjukhuset, Huddinge Stockholm, Sweden Hematologkliniken Norrlands Universitetssjukhus Umeå, Sweden Hematologisektionen Medicincentrum Akademiska sjukhuset Uppsala, Sweden United Kingdom Royal Bournemouth Hospital Dept. of Haematology Bournemouth, United Kingdom Cardiff and Vale NHS Trust University Hospital of Wales Cardiff, United Kingdom Stobhill Hospital Department of Haematology Glasgow, United Kingdom Leeds General Infirmary Department of Haematology Leeds, United Kingdom Leicester Royal Infirmary Department of Oncology & Haematology Leicester, United Kingdom Nottingham City Hospital NHS Trust Nottingham, United Kingdom Less <<
NCT01161615	Acute Tendonitis ... More >> Bursitis Less <<	Phase 3	Completed	-	-
NCT03127592	Pain, Acute	Phase 3	Not yet recruiting	December 18, 2018	-
NCT01265576	HCC	Phase 2	Unknown	April 2016	United States, California ... More >> Vicus Clinical Site Berkeley, California, United States, 94704 United States, Georgia Vicus Clinical Site Atlanta, Georgia, United States, 30318 United States, New Jersey Vicus Clinical Site New Brunswick, New Jersey, United States Vicus Clinical Site Newark, New Jersey, United States, 07103 Vicus Clinical Site Paterson, New Jersey, United States, 07503 United States, New York Vicus Clinical Site Buffalo, New York, United States, 14263 Vicus Clinical Site New York, New York, United States, 10016 United States, Pennsylvania Vicus Clinical Site Philadelphia, Pennsylvania, United States United States, Texas Vicus Clinical Site Houston, Texas, United States, 77024 Vicus Clinical Site Houston, Texas, United States, 77030 Less <<
NCT01968005	Low Back Pain	Phase 3	Completed	-	United States, California ... More >> Carlsbad, California, United States, 92008 United States, Florida Miami, Florida, United States, 33155 United States, New York New York, New York, United States, 10022 United States, Ohio Zanesville, Ohio, United States, 43701 United States, Texas Dallas, Texas, United States, 75234 El Paso, Texas, United States, 79902 San Antonio, Texas, United States, 78207 Less <<
NCT00293111	Multiple Myeloma	Phase 2	Terminated	-	United States, Florida ... More >> H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University School of Medicine Atlanta, Georgia, United States, 30322 United States, Maryland Johns Hopkins School of Medicine Baltimore, Maryland, United States, 21231 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, North Carolina University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01735370	Fasting	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India Less <<
NCT01198834	Ankle Sprains	Phase 3	Completed	-	-
NCT01118572	Post Operative Pain	Phase 3	Completed	-	Japan ... More >> Chubu, Japan Chugoku, Japan Hokkaido, Japan Kansai, Japan Kantou, Japan Kyusyu, Japan Shikoku, Japan Touhoku, Japan Less <<
NCT01746719	Fasting	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India Less <<
NCT01749228	Healthy	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India Less <<
NCT01735383	Fed	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India Less <<
NCT01827865	Fasting	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India, 380 015 Less <<
NCT01831687	Fasting	Phase 1	Completed	-	India ... More >> Veeda Clinical Research Pvt. Ltd. Ahmedabad, Gujarat, India, 380 015 Less <<
NCT02881619	Medicaments Substances in Ther... More >>apeutic Use Less <<	Phase 4	Completed	-	-
NCT01857817	Prostatic Neoplasms	Phase 2	Terminated(Low patient recruit... More >>ment) Less <<	-	United States, Arkansas ... More >> Highlands Oncology Group Fayetteville, Arkansas, United States, 72703 United States, California Redwood Regional Medical Group Santa Rosa, California, United States, 95403 United States, Colorado Advanced Urology Parker, Colorado, United States, 80134 United States, Florida Manatee Medical Research Institute, LLC Bradenton, Florida, United States, 34205 Baptist Cancer Institute Jacksonville, Florida, United States, 32207 United States, Illinois Midwestern Regional Medical Center Zion, Illinois, United States, 60099 United States, Michigan Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Detroit Clinical Research Center, PC Lansing, Michigan, United States, 48912 United States, Minnesota Adult & Pediatric Urology Sartell, Minnesota, United States, 56377 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 AccuMed Research Associates Garden City, New York, United States, 11530 Premier Medical Group of the Hudson Valley PC Poughkeepsie, New York, United States, 12601 United States, Texas Hendrick Cancer Center Abilene, Texas, United States, 79601 Oncology Consultants, P.A. Houston, Texas, United States, 77030 United States, Washington Virginia Mason Medical Center Seattle, Washington, United States, 98101 Medical Oncology Associates, PS Spokane, Washington, United States, 99208 Less <<
NCT02695381	Acute Delayed Onset Muscle Sor... More >>eness (DOMS) Less <<	Phase 3	Completed	-	United States, California ... More >> Lotus Clinical Research Pasadena, California, United States, 91195 Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.48mL 0.70mL 0.35mL	17.40mL 3.48mL 1.74mL	34.80mL 6.96mL 3.48mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed